"We are clinical pharmacologists and drug developers with innate ability to aid in solving drug development challenges and developing straight forward strategies for successful therapies."
Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach.
Authors: Julie M Bullock, Tiffany Lin, Sanela Bilic
J Clin Pharmacol 2017 Oct;57 Suppl 10:S105-S115
D3 Medicine, a Certara USA Company, Parsippany, NJ, USA.
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor.
Authors: Kyriakos P Papadopoulos, Randi Isaacs, Sanela Bilic, Kerstin Kentsch, Heather A Huet, Matthias Hofmann, Drew Rasco, Nicole Kundamal, Zhongwhen Tang, Jennifer Cooksey, Amit Mahipal
Cancer Chemother Pharmacol 2015 May 27;75(5):887-95. Epub 2015 Feb 27.
South Texas Accelerated Research Therapeutics, 4383 Medical Drive, Suite 4021, San Antonio, TX, 78229, USA,
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
Authors: Swaminathan P Iyer, Joseph Taddeus Beck, A Keith Stewart, Jatin Shah, Kevin R Kelly, Randi Isaacs, Sanela Bilic, Suman Sen, Nikhil C Munshi
Br J Haematol 2014 Nov 19;167(3):366-75. Epub 2014 Aug 19.
Houston Methodist Cancer Center, Weill Cornell Medical College, Houston, TX, USA.
American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA.
Authors: Karen Thudium, Sanela Bilic, Douglas Leipold, William Mallet, Surinder Kaur, Bernd Meibohm, Hans Erickson, Jay Tibbitts, Hong Zhao, Manish Gupta
MAbs 2013 Jan-Feb;5(1):5-12. Epub 2012 Dec 19.
Novartis Pharmaceuticals, Clinical Pharmacology, Oncology Business Unit, Florham Park, NJ, USA.
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.
Authors: Sunil Sharma, Elisabeth G de Vries, Jeffrey R Infante, Corina N Oldenhuis, Jourik A Gietema, Lin Yang, Sanela Bilic, Katie Parker, Michael Goldbrunner, Jeffrey W Scott, Howard A Burris
Invest New Drugs 2014 Feb 16;32(1):135-44. Epub 2013 Apr 16.
Huntsman Cancer Institute, Division of Medical Oncology, University of Utah, 2000 Circle of Hope Drive, Suite 3380, Salt Lake City, UT, 84112, USA,
Conference report: hot topics in antibody-drug conjugate development.
Authors: Karen Thudium, Sanela Bilic
Bioanalysis 2013 Dec;5(24):2989-93
Novartis Pharmaceuticals, Clinical Pharmacology, Oncology Business Unit, East Hanover, NJ, USA.
Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper.
Authors: Boris Gorovits, Stephen C Alley, Sanela Bilic, Brian Booth, Surinder Kaur, Phillip Oldfield, Shobha Purushothama, Chetana Rao, Stacy Shord, Patricia Siguenza
Bioanalysis 2013 May;5(9):997-1006
Pfizer, 1 Burtt Road, Andover, MA 01810, USA.
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.
Authors: John C Byrd, Thomas J Kipps, Ian W Flinn, Maureen Cooper, Olatoyosi Odenike, Jennifer Bendiske, John Rediske, Sanela Bilic, Jyotirmoy Dey, Johan Baeck, Susan O’Brien
Leuk Lymphoma 2012 Nov 12;53(11):2136-42. Epub 2012 Jun 12.
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.
Authors: William Bensinger, Richard T Maziarz, Sundar Jagannath, Andrew Spencer, Simon Durrant, Pamela S Becker, Brett Ewald, Sanela Bilic, John Rediske, Johan Baeck, Edward A Stadtmauer
Br J Haematol 2012 Oct 4;159(1):58-66. Epub 2012 Aug 4.
Clinical Research Division, Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA 98109-1024, USA.
Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies.
Authors: Seth A Ettenberg, Olga Charlat, Michael P Daley, Shanming Liu, Karen J Vincent, Darrin D Stuart, Alwin G Schuller, Jing Yuan, Beatriz Ospina, John Green, Qunyan Yu, Renee Walsh, Sharon Li, Rita Schmitz, Holger Heine, Sanela Bilic, Lance Ostrom, Rebecca Mosher, K Felix Hartlepp, Zhenping Zhu, Stephen Fawell, Yung-Mae Yao, David Stover, Peter M Finan, Jeffery A Porter, William R Sellers, Ingo M Klagge, Feng Cong
Proc Natl Acad Sci U S A 2010 Aug 16;107(35):15473-8. Epub 2010 Aug 16.
Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.